Acasti Pharma Announces the Election of Its Directors, Advisory Resolution Approving Compensation, Amendments to Its Stock Op...
October 01 2020 - 4:30PM
Acasti Pharma Inc. (“Acasti” or the “Corporation”) (NASDAQ: ACST –
TSX-V: ACST), announces the voting results for the matters listed
in its management information circular and proxy statement dated
August 31, 2020 (the “Circular”) held at its Annual and Special
Meeting of Shareholders on September 30, 2020 (the “AGM”).
For further information on the voting results of
the resolution passed during the AGM, please refer to the Report of
Voting Results available on SEDAR at www.sedar.com.
Election of Directors
At the AGM, the following individuals were
elected as directors of the Corporation for the ensuing year:
Roderick N. Carter, Jean-Marie (John) Canan, Jan D’Alvise and
Donald Olds.
Appointment of Auditors
At the AGM, KPMG LLP were appointed as the
Corporation’s auditors for the ensuing fiscal year and the
directors were authorized to fix their remuneration.
Advisory Vote on the Compensation of
Named Executive Officers
At the AGM, shareholders passed an advisory
(non-binding) resolution approving the compensation of the
Corporation’s named executive officers.
Advisory Vote on the Frequency of Future
Shareholder “say-on-pay” Votes
At the AGM, shareholders passed an advisory
(non-binding) resolution approving the option of having an advisory
(non-binding) vote approving the compensation of the Corporation’s
named executive officers once every year.
Amendments to the Corporation Stock
Option Plan and Equity Incentive Plan
At the AGM, disinterested shareholders approved
amendments to the Corporation’s stock option plan, as more
particularly described in the Circular.
At the AGM, disinterested shareholders also
approved amendments to the Corporation’s equity incentive plan, as
more particularly described in the Circular.
The amendments to the Stock Option Plan and the
Equity Incentive Plan are subject to TSX-V final approval.
Adoption of Amended & Restated
General By-Law
At the AGM, shareholders passed a resolution to
approve, ratify and confirm the adoption of the amended and
restated general by-law of the Corporation, as more particularly
described in the Circular.
Forward Looking Statements
Statements in this press release that are not
statements of historical or current fact constitute
“forward-looking information” within the meaning of Canadian
securities laws and “forward-looking statements” within the meaning
of U.S. federal securities laws (collectively, “forward-looking
statements”). Such forward-looking statements involve known and
unknown risks, uncertainties, and other unknown factors that could
cause the actual results of Acasti to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. In addition to statements which
explicitly describe such risks and uncertainties, readers are urged
to consider statements labeled with the terms “believes,” “belief,”
“expects,” “intends,” “anticipates,” “potential,” “should,” “may,”
“will,” “plans,” “continue”, “targeted” or other similar
expressions to be uncertain and forward-looking. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press
release.
The forward-looking statements contained in this
press release are expressly qualified in their entirety by this
cautionary statement, the “Special Note Regarding Forward-Looking
Statements” section contained in Acasti’s latest annual report on
Form 10-K and latest quarterly report on Form 10-Q, which are
available on SEDAR at www.sedar.com, on EDGAR at
www.sec.gov/edgar/shtml, and on the investor section of Acasti’s
website at www.acastipharma.com. All forward-looking statements in
this press release are made as of the date of this press release.
Acasti does not undertake to update any such forward-looking
statements whether as a result of new information, future events or
otherwise, except as required by law. The forward-looking
statements contained herein are also subject generally to
assumptions and risks and uncertainties that are described from
time to time in Acasti’s public securities filings with the
Securities and Exchange Commission and the Canadian securities
commissions, including Acasti’s latest annual report on Form 10-K
under the caption “Risk Factors”.
Neither NASDAQ, the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Acasti Contact:Jan
D’AlviseChief Executive OfficerTel: 450-686-4555Email:
info@acastipharma.comwww.acastipharma.com
U.S.
Contact:Crescendo Communications, LLCTel:
212-671-1020Email: ACST@crescendo-ir.com
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acasti Pharma (NASDAQ:ACST)
Historical Stock Chart
From Sep 2023 to Sep 2024